Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat

Neuroscience and Biobehavioral Reviews

Volumn 20, Issue 2, 1996, Pages 325-339

  Wadenberg, Marie Louise ^a,b  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Catalepsy; Dopamine; Parkinsonism; Rat; Receptor; Serotonin

Indexed keywords

2 DIPROPYLAMINO 5 FLUORO 8 HYDROXYTETRALIN; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPRENOLOL; ANTIDEPRESSANT AGENT; BETAXOLOL; CLOZAPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; HALOPERIDOL; IPSAPIRONE; NEUROLEPTIC AGENT; PERPHENAZINE; PINDOLOL; RACLOPRIDE; RITANSERIN; SEROTONIN 1A AGONIST; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; ZIMELDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CLINICAL TRIAL; DEPRESSION; DOPAMINERGIC SYSTEM; EXTRAPYRAMIDAL SYNDROME; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; LOCOMOTION; MEDIAN RAPHE NUCLEUS; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR OCCUPANCY; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029763907     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/0149-7634(95)00057-7     Document Type: Article

References (135)

1. 1. Ahlenius, S. Strategies for the choice of animal models in the evaluation of atypical antipsychotic drugs. In: Palomo, T.; Archer, T.; Beninger, B. J., eds. Schizophrenia, movement disorders and cognitive disorders relating to aging. London: Farrend Press; 1994:17-31.
2. 2. Ahlenius, S.; Hillegaart, V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre-and postsynaptic inhibition of dopaminergic neurotransmission. Pharmacol. Biochem. Behav. 24:1409-1415; 1986.
3. 3. Ahlenius, S.; Hillegaart, V.; Thorell, G.; Magnusson, O.; Fowler, C. J. Suppression of exploratory locomotor activity and increase in dopamine turnover following the local application of cisflupenthixol into limbic projection areas of the rat striatum. Brain Res. 402:131-138; 1987.
4. 4. Ames, D.; Wirshing, W. C.; Marder, S. R.; Yuwiler, A.; Brammer, G. L.; Midha, K. K.; Van Putten, T. Adjunctive fluoxetine in haloperidol-stabilized schizophrenics. Neuropsychopharmacology 9:116S; 1993.
5. 5. Andén, N.-E. Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs. J. Pharmacol. 24:905-906; 1972.
6. 6. Andersen, P. H.; Braestrup, C. Evidence for different states of the dopamine D1 receptor: Clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor. J. Neurochem. 47:1822-1831; 1986.
7. 3H-SCH 23390 to dopamine D1 receptors in vivo. Life Sci. 38:1507-1515; 1986.
8. 8. Ariyanayagam, A. D.; Handley, S. L. Effect of sensory stimulation on the potency of cataleptogens. Psychopharmacology 41:165-167; 1975.
9. 9. Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G.; Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikström, H. 8-hydroxy-2-(di-n-propylamino)tetraline, a new centrally acting 5-hydroxytryptamine receptor agonist. J. Med. Chem. 24:921-923; 1981.
10. 10. Bacher, N. M.; Lewis, H. A. Low-dose propranolol in tardive dyskinesia. Am. J. Psychiatry 137:495-497; 1980.
11. 11. Baldessarini, R. J. Drugs and the treatment of psychiatric disorders. In: Goodman, Gilman, A.; Rail, T. W.; Nies, A. S.; Taylor, P., eds. The pharmacological basis of therapeutics. New York: Pergamon Press; 1990:383-435.
12. 12. Balsara, J. J.; Jadhav, J. H.; Chandorka, A. G. Effects of drugs influencing central serotonergic mechanisms of haloperidol-induced catalepsy. Psychopharmacology 62:67-69; 1979.
13. 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 35:1885-1893; 1984.
14. 2) receptors. Eur. J. Pharmacol. 129:367-370; 1986.
15. 1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J. Pharmacol. Exp. Ther. 258:58-65; 1991.
16. 16. Boissier, J. R.; Simon, P. Un test simple pour l'étude quantitative de la catatonie provoquée chez le rat par les neuroleptiques. Application à l'étude des anticatatoniques. Thérapie 18:1257-1277; 1963.
17. 17. Bouchard, R. H.; Pourcher, E.; Vincent, P. Fluoxetine and extrapyramidal side effects (Letter). Am. J. Psychiatry 146:1352-1353; 1989.
18. 18. Bowker, R. M.; Westlund, K. N.; Coulter, J. D. Serotonergic projections to the spinal cord from the midbrain in the rat: An immunocytochemical and retrograde transport study. Neurosci. Lett. 24:221-226; 1981.
19. 19. Brand, U.; Dittmann, E.-Ch.; Menge, H. G. Methodisches Vorgehen zur Erfassung "kataleptischer Zustände" bei der Ratte. Arzneimittel-Forsch. 28:1504-1505; 1978.
20. 20. Brod, T. M. Fluoxetine and extrapyramidal side effects (Letter). Am. J. Psychiatry 146:1353; 1989.
21. 21. Broekkamp, R. W.; Cervo, S. K.; Berendsen, H. H. G.; van Delft, A. M. L. Effect of metergoline, fenfluramine and 8-OH-DPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedeberg's Arch. Pharmacol. 338:191-195; 1988.
22. 22. Bruhwyler, J.; Chleide, E.; Mercier, M. Clozapine: An atypical neuroleptic. Neurosci. Biobehav. Rev. 14:357-363; 1990.
23. 23. Brune, G. G.; Morpurgo, C.; Bielkus, A.; Kobayashi, T.; Tourlentes, T. T.; Himwich, H. E. Relevance of drug-induced extrapyramidal reactions to behavioral changes during neuroleptic treatment. I. Treatment with trifluoperazine singly and in combination with trihexyphenidyl. Comprehens. Psychiatry 3:227-234; 1962.
24. 24. Campbell, A.; Baldessarini, R. J.; Cremens, M. C. Dose-catalepsy response to haloperidol in rat: Effects of strain and sex. Neuropharmacology 27:1197-1199; 1988.
25. 25. Casey, D. E. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:547-548; 1989.
26. 1-adrenoceptorantagonists, LERS Monograph Series, vol. 1. New York: Raven Press; 1983:31-42.
27. 3H) spiperone in the rat. Brain Res. 172:360-366; 1979.
28. 1 antagonist in clinical trial. Trends Pharmacol. Sci. 11:185; 1990.
29. 29. Chouinard, G.; Sultan, S. A case of Parkinson's disease exacerbated by fluoxetine. Human Psychopharmacol. 7:63-66; 1992.
30. 30. Claus, A.; Bollen, J.; De Cuyper, H.; Eneman, M.; Malfroid, M.; Peuskens, J.; Heylen, S. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicenter double-blind comparative study. Acta Psychiat. Scand. 85:295-305; 1992.
31. 31. Costall, B.; Hui, S.-C. G.; Naylor, R. J. Correlation between multitest and single test catalepsy assessment. Neuropharmacology 17:761-764; 1978.
32. 32. Costall, B.; Naylor, R. J. Neuroleptic and non-neuroleptic catalepsy. Arzneimittel Forsch, 23:674-684; 1973.
33. 33. Costall, B.; Naylor, R. J. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacology 34:233-241; 1974.
34. 34. Costall, B.; Olley, J. E. Cholinergic-and neuroleptic-induced catalepsy: Modification by lesions in the caudate-putamen. Neuropharmacology 10:297-306; 1971.
35. 35. Costain, D. W.; Green, A. R. β-Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine. Br. J. Pharmacol. 64:193-200; 1978.
36. 36. Courvoisier, S.; Ducrot, R.; Julou, L. Nouveaux aspects expérimentaux de l'activité centrale des dérivés de la phénothiazine. In: Garattini, S.; Ghetti, V., eds. Psychotropic drugs. Amsterdam: Elsevier; 1957:373-391.
37. 37. Deutch, A. Y.; Moghaddam, B.; Innis, R. B.; Krystal, J. H.; Aghajanian, G. K.; Bunney, B. S.; Charney, D. S. Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Res. 4:121-156; 1991.
38. 38. Duvoisin, R. C. Par̀kinsonism: Animal analogues of human movement disorder. In: Yahr, M. D., ed. The basal ganglia. New York: Raven Press; 1976:293-303.
39. 39. Ellenbroek, B. A. Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57:1-78; 1993.
40. 40. Ellenbroek, B. A.; Cools, A. R. The paw test: An animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci. 42:1205-1213; 1988.
41. 41. Elliott, P. J.; Close, S. P.; Walsh, A. G.; Hayes, A. G.; Marriott, A. S. Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents. J. Neural Transm. (Parkinson's-Disease) 2:79-89; 1990.
42. 42. Elliott, P. J.; Walsh, D. M.; Close, S. P.; Higgins, G. A.; Hayes, A. G. Behavioural effects of serotonin agonists and antagonists in the rat and marmoset. Neuropharmacology 29:949-956; 1990.
43. 43. Farde, L.; Wiesel, F.-A.; Nordström, A.-L.; Sedvall, G. D1-and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31; 1989.
44. 44. Ferré, S.; Guix, T.; Prat, G.; Jane, F.; Casas, M. Is experimental catalepsy properly measured? Pharmacol. Biochem. Behav. 35:753-757; 1990.
45. 45. Freyhan, F. A. The relationship of drug-induced neurological phenomena on therapeutic outcome. In: Bordeleau, J. M., ed. Extrapyramidal system and neuroleptics. Montréal: Editions Psychiatriques; 1961:453-4641
46. 46. Fuenmayor, L. D.; Vogt, M. The influence of cerebral 5-hydroxytryptamine on catalepsy induced by brain-amine depleting neuroleptics or by cholinomimetics. Brain J. Pharmacol. 67:309-318; 1979.
47. 2 serotoninreceptors. J. Med. Chem. 31:5-7; 1988.
48. 2 receptors. Br. J. Pharmacol. 84:743-753; 1985.
49. 49. Green, A. R.; Grahame-Smith, D. G. (-)Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature 262:594-596; 1976.
50. 50. Gudelsky, G. A.; Koenig, J. I.; Meltzer, H. Y. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Neuropharmacology 25:1307-1313; 1986.
51. 51. Gumulka, W.; Kostowski, W.; Czlonkowski, A. Role of 5-HT in the action of some drugs affecting extrapyramidal system. Pharmacology 10:363-372; 1973.
52. 52. Hafner, H.; Behrens, S.; De Vry, J.; Gattaz, W. F. An animal model for the effects of oestradiol on dopamine-mediated behaviour: Implications for sex differences in schizophrenia. Psychiat. Res. 38:125-134; 1991.
53. 53. Hannigan, J. H. The ontogeny of SCH 23390-induced catalepsy in male and female rats exposed prenatally to ethanol. Alcohol 7:11-16; 1990.
54. 54. Hicks, P. B. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 47:1609-1615; 1990.
55. 55. Hicks, P. E.; Schoemacher, H.; Langer, S. Z. 5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. Eur. J. Pharmacol. 105:339-342; 1984.
56. 56. Hillegaart, V. Effects of local application of 5-HT and 8-OH-DPAT into the dorsal and median raphe nuclei on motor activity in the rat. Physiol. Behav. 48:143-148; 1990.
57. 57. Hillegaart, V.; Ahlenius, S. Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behavior and catalepsy in rats: Behavioral profile comparisons between raclopride, haloperidol and preclamol. Pharmacol. Toxicol. 60:350-354; 1987.
58. 58. Hillegaart, V.; Ahlenius, S.; Fowler, Ch. J.; Magnusson, O. Increased duration of dopamine receptor antagonist-induced effects on both behaviour and striatal dopamine turnover by repeated testing in rats. Pharmacol. Toxicol. 63:114-117; 1988.
59. 59. Hillegaart, V.; Ahlenius, S.; Magnusson, O.; Fowler, Ch. J. Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response. Pharmacol. Biochem. Behav. 27:159-164; 1987.
60. 60. Hillegaart, V.; Wadenberg, M.-L.; Ahlenius, S. Effects of 8-OH-DPAT on motor activity in the rat. Pharmacol. Biochem. Behav. 32:797-800; 1989.
61. 61. Hinson, R. E.; Poulos, C. X.; Thomas, W. L. Learning in tolerance to haloperidol-induced catalepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry 6:395-398; 1982.
62. 62. Hippius, H. The history of clozapine. Psychopharmacology 99:S3-S5; 1989.
63. 63. Hjorth, S.; Carlsson, A. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur. J. Pharmacol. 129:131-138; 1986.
64. 64. Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikström, H.; Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G. 8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT receptor stimulating activity. J. Neural Transm. 55:169-188; 1982.
65. 65. Hollander, M.; Wolfe, D. Nonparametric statistical methods. New York: Wiley; 1973.
66. 66. Hollister, L. E. Antipsychotic medications and the treatment of schizophrenia. In: Barchas, J. D.; Berger, P. A.; Ciaranello, R. D.; Elliott, G. R., eds. Psychopharmacology: From theory to practice. New York: Oxford University Press; 1984:121-150.
67. 3H]ketanserin. Eur. J. Pharmacol. 118:13-23; 1985.
68. 5H-dibenzo(b,e)-1,4-diazepine-10. Mitteilungen über siebengliedrige Heterocyclen. Helv. Chim. Acta 50:1588; 1967.
69. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518; 1988.
70. 70. Iorio, L. C; Barnett, A.; Leitz, F. H.; Houser, V. P.; Korduba, C. A. SCH 23390, a potential benzamide antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 226:462-468; 1983.
71. 71. Jansen Steur, E. N. H. Increase of Parkinson disability after fluoxetine medication. Neurology 43:211-213; 1993.
72. 72. Janssen, P. A. J.; Niemegeers, C.; Awouters, F.; Schellekens, K. H. L.; Megens, A. A. H. P.; Meert, T. F. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244:685-693; 1988.
73. 1A receptors in the mediation of exploratory locomotor activity in the rat. J. Psychopharmacol. 3:32-35; 1989.
74. 74. Keppel Hesselink, J. M. Exacerbation of Parkinson's disease by fluoxetine (letter). Human Psychopharmacol. 7:411-412; 1992.
75. 75. Ketai, R. Interaction between fluoxetine and neuroleptics. Am. J. Psychiatry 150:836-837; 1993.
76. 76. Kinon, B. J.; Kane, J. M. Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops. Psychopharmacology 98:465-471; 1989.
77. 77. Klockgether, T.; Schwarz, M.; Turski, L.; Wohlfarth, S.; Sontag, K.-H. Rigidity and catalepsy after injections of muscimol into the ventromedial thalamic nucleus: an electromyographic study in the rat. Exp. Brain Res. 58:559-569; 1985.
78. 2 receptors in the rat brain. Biochem. Pharmacol. 34:2251-2259; 1985.
79. 79. Kolpakov, V. G.; Gilinsky, M. A.; Alekhina, T. A.; Barykina, N. N.; Nikulina, E. M.; Voitenko, N. N.; Kulikov, A. V.; Shtilman, N. I. Experimental studies on genetically determined predisposition to catatonia in rats as a model of schizophrenia. Behav. Process. 14:319-342; 1987.
80. 80. Korsgaard, S.; Friis, T. Effects of mianserin in neuroleptic-induced parkinsonism. Psychopharmacology 88:109-111; 1986.
81. 81. Kostowski, W.; Gumulka, W.; Czlonkowski, A. Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res. 48:443-446; 1972.
82. 82. Krupp, P.; Monka, C. Situation report, 31 March 1982. Sandoz Document, 26 April 1982. Sandoz, Basel, Switzerland.
83. 83. Kuschinsky, K.; Hornykiewicz, O. Morphine catalepsy in the rat. Relation to striatal dopamine metabolism. Eur. J. Pharmacol. 19:119-122; 1972.
84. 1 receptor blockade. Kirjapaino Grafia Oy (Thesis), Finland; 1992.
85. 85. Lappalainen, J.; Hietala, J.; Koulu, M.; Syvälahti, E. Neurochemical effects of chronic coadministration of ritanserin and halperidol: comparison with clozapine effects. Eur. J. Pharmacol. 190:403-407; 1990.
86. 86. Levinson, D. F.; Simpson, G. Serious nonextrapyramidal adverse effects of neuroleptics: sudden death, agranulocytosis, and hepatotoxicity. In: Meltzer, H., ed. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987:1431-1436.
87. 2 antagonist. Mol. Pharmacol. 27:600-611; 1985.
88. 2)-receptor binding sites: Effects of neuronal lesions. In: Mandel, P.; de Feudis, F. V., eds. CNS receptors - From molecular pharmacology to behaviour. New York: Raven Press; 1983: 373.
89. 89. McEvoy, J. P. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J. Clin. Psychopharmacol. 3:288-302; 1983.
90. 90. McMillen, B. A.; Scott, S. M.; Davanzo, E. A. Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J. Pharm. Pharmaco. 40:885-887; 1988.
91. 91. Meco, G.; Bedini, L.; Bonifati, V.; Sonsini, U. Ritanserin in tardive dyskinesia: A double-blind crossover study versus placebo. Curr. Ther. Res. 46:884-894; 1989.
92. 92. Meco, G.; Bedini, L.; Bonifati, V.; Sonsini, U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr. Ther. Res. 46:876-883; 1989.
93. 93. Meltzer, H. Y. Dopaminergic and serotonergic mechanisms in the action of clozapine. In: Tamminga, C. A.; Schulz, S. C., eds. Advances in neuropsychiatry and psychopharmacology, vol. 1. Schizophrenia research. New York: Raven Press; 1991:333-338.
94. i values. J. Pharmacol. Exp. Ther. 251:238-246; 1989.
95. 95. Meltzer, H. Y.; Young, M.; Metz, J.; Fang, V. S.; Schyve, P. M.; Arora, R. C. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J. Neural Transm. 45:165-175; 1979.
96. 96. Menge, H. G.; Brand, U. Zur Differenzierung der Wirkung kataleptogener Stoffe. Arzneimittel-Forsch. 28:1506-1507; 1978.
97. 97. Middlemiss, D. N.; Fozard, J. 8-Hydroxy-2-(di-n-propy-lamino)tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur. J. Pharmacol. 30:151-153; 1983.
98. 1A receptor antagonist (S)-UH-301 in rodents and monkeys. Brain Res. Bull. 29:901-904; 1992.
99. 99. Morpurgo, C. Antiparkinson drugs and neuroleptics. In: Himwich, W. A.; Schadé, J. P., eds. Progress in Brain Research, vol. 16. Amsterdam: Elsevier; 1965: 121-134.
100. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287-294; 1986.
101. 1A receptors. Chichester: Ellis Horwood; 1987:67-81.
102. 102. Reynolds, G. P.; Czudek, C. New approaches to the drug treatment of schizophrenia. Adv. Pharmacol. 32:461-503; 1995.
103. 103. Ross, S.; Ögren, S. O.; Renyi, A. L. (Z)Dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl)propene (H102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake. Acta Pharmacol. Toxicol. 39:152-166; 1976.
104. 104. Salmi, P.; Karlsson, T.; Ahlenius, S. Antagonism by SCH-23,390 of clozapine-induced hypothermia in the rat. Eur. J. Pharmacol. 253:67-73; 1994.
105. 105. Salmi, P.; Samuelsson, J.; Ahlenius, S. A new computer-assisted two-way avoidance conditioning equipment for rats: Behavioral and pharmacological validation. J. Pharmacol. Toxicol. Methods 32:155-159; 1994.
106. 106. Sanberg, P. R.; Giordano, M.; Bunsey, M. D.; Norman, A. B. The catalepsy test: Its ups and downs. Behav. Neurosci. 102:748-759; 1988.
107. 107. Sanberg, P. R.; Pisa, M.; Faulks, I. J.; Fibiger, H. C. Experiential influences on catalepsy. Psychopharmacology 69:225-226; 1980.
108. 3) as an autoreceptor. Adv. Biosci. 82:51-54; 1991.
109. 109. Seeman, P. Brain dopamine receptors. Pharmacol. Rev. 32:229-313; 1980.
110. 110. Seeman, P. Dopamine receptors. Clinical correlates. In: Bloom, F. E., Kupfer, D. J., eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press; 1995:295-302.
111. 4 receptors elevated in schizophrenia. Nature 365:441-445; 1993.
112. 112. Shipley, J. E.; Rowland, N.; Antelman, S. M.; Buggy, J.; Edwards, D. J.; Shapiro, A. P. Increased amphetamine stereotypy and longer haloperidol catalepsy in spontaneously hypertensive rats. Life Sci. 28:745-753; 1981.
113. 113. Siegel, S.; Castellan, N. J., Jr. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill; 1988.
114. 114. Simon, P.; Langwinski, R.; Boissier, J.-R. Comparaison de différents tests d'évaluation de la catalepsie chez le rat. Thérapie 24:985-995; 1969.
115. 115. Stanley, M. E.; Glick, S. D. Interaction of drug effects with testing procedures in the measurement of catalepsy. Neuropharmacology 15:393-394; 1976.
116. 116. Steinbusch, H. W. M.; Nieuwenhuys, R. The raphe nuclei of the rat brainstem: a cytoarchitectonic and immunohistochemical study. In: Emson, P. C., ed. Chemical neuroanatomy. New York: Raven Press; 1983:131-207.
117. 117. Stern, J. M. Nursing posture is elicited rapidly in maternally naive, haloperidol-treated female and male rats in response to ventral trunk stimulation from active pups. Horm. Behav. 25:504-517; 1991.
118. 118. Tamminga, C. A.; Gerlach, J. New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer, H. Y., ed. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987:1129-1140.
119. 119. Tate, J. L. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine (Letter). Am. J. Psychiatry 146:399-400; 1989.
120. 120. Tedeschi, D. H.; Tedeschi, R. E.; Cook, L.; Mattis, P. A.; Fellows, E. J. The neuropharmacology of trifluoperazine: A potent psychotherapeutic agent. Arch. Int. Pharmacodyn. 122:129-143; 1959.
121. 121. Timsit, J. Sur l'activité cataleptigène de quelques dérivés de la butyrophénone. Thérapie 21:1453-1471; 1966.
122. 122. Wadenberg, M.-L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural Transm. 89:49-59; 1992.
123. 123. Wadenberg, M.-L. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat: implications for the mechanism of action of atypical antipsychotic drugs. Akademitryck AB, Edsbruk (Thesis), Sweden; 1993.
124. 124. Wadenberg, M.-L.; Ahlenius, S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J. Neural Transm. 83:43-53; 1991.
125. 2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat. Eur. J. Pharmacol. 294:247-251; 1995.
126. 126. Wadenberg, M.-L.; Ahlenius, S.; Svensson, T. H. Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: Implications for the mechanism of action of clozapine. Psychopharmacology 110:273-279; 1993.
127. 2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacol. Biochem. Behav. 47:509-513; 1994.
128. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 34:495-499; 1995.
129. 129. Wadenberg, M.-L.; Hillegaart, V.; Berge, O.-G. Supraspinal mediation of dopamine-serotonin interactions in extrapyramidal motor functions in the rat. NeuroReport 4:59-61; 1993.
130. 2 receptor blocking agent ritanserin in the rat. Soc. Neurosci. Abstr. 153:4; 1995.
131. 131. Waldmeier, P. C.; Delini-Stula, A. Serotonin-dopamine interactions in the nigrostriatal system. Eur. J. Pharmacol. 55:363-373; 1979.
132. 132. Wand, P.; Kuschinsky, K.; Sontag, K. H. Morphine-induced muscular rigidity in rats. Eur. J. Pharmacol. 24:189-193; 1973.
133. 133. Wilbur, R.; Kulik, F. A. Propranolol (Inderal) for tardive dyskinesia and extrapyramical side effects from neuroleptics: possible involvement of beta-adrenergic mechanisms. Prog. Neuro-Psychopharmacol. 4:627-632; 1981.
134. 134. Wirth, W.; Gösswald, R.; Hörlein, U.; Risse, K. H.; Kreiskott, H. Zur Pharmakologie acylierte Phenothiazin-Derivate. Arch. Int. Pharmacodyn. 115:1-31; 1958.
135. 135. Young, K. A.; Zavodny, R.; Hicks, P. B. Effects of serotonergic agents on apomorphine-induced locomotor activity. Psychopharmacology 110:97-102; 1993.